Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.

FDA NDA acceptance positions zipalertinib for post-systemic-therapy EGFR ex20ins NSCLC, with a February 27, 2027 PDUFA target ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, today announced that new clinical data from its non-small cell lung ...

Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.

Suzhou Puhe Biopharma Co. Ltd. presented promising preclinical profile data on PH009-1, a novel fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Besides ...

EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, even after undergoing systemic therapy, patients may have oligometastatic ...

Regorafinib outcomes from the population-based South Australian mCRC registry (SAmCRCR). Time from diagnosis to 1st line immunotherapy (IOT) and its challenges, in a retrospective, multicenter study ...

Black Diamond Therapeutics, Inc. BDTX is building its equity story around a single, high-leverage asset: silevertinib, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) ...

Cancer-Control Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer With BRCA Gene or Tumor Suppressor Mutations Undergoing 177-Lutetium Prostate-Specific Membrane Antigen ...

Patients prescribed the combination therapy should be given anticoagulant prophylaxis to prevent VTE during the first 4 months of treatment. The Food and Drug Administration (FDA) has approved ...